Total Payments
$749.97
2024 Payments
$249.47
Companies
9
Transactions
29
Medicare Patients
5,047
Medicare Billing
$1.0M
Payment Breakdown by Category
Food & Beverage$616.91 (82.3%)
Education$133.06 (17.7%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $616.91 | 20 | 82.3% |
| Education | $133.06 | 9 | 17.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $414.37 | 7 | $0 (2024) |
| Janssen Biotech, Inc. | $69.02 | 5 | $0 (2018) |
| Allergan Inc. | $67.77 | 4 | $0 (2018) |
| Insmed, Inc. | $60.62 | 4 | $0 (2023) |
| Merck Sharp & Dohme Corporation | $37.88 | 3 | $0 (2020) |
| Gilead Sciences, Inc. | $37.20 | 3 | $0 (2019) |
| Janssen Pharmaceuticals, Inc | $28.48 | 1 | $0 (2023) |
| BOSTON SCIENTIFIC CORPORATION | $20.63 | 1 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $14.00 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $249.47 | 3 | ABBVIE INC. ($249.47) |
| 2023 | $209.62 | 6 | ABBVIE INC. ($164.90) |
| 2022 | $32.48 | 2 | Insmed, Inc. ($32.48) |
| 2021 | $20.63 | 1 | BOSTON SCIENTIFIC CORPORATION ($20.63) |
| 2020 | $49.78 | 4 | Merck Sharp & Dohme Corporation ($37.88) |
| 2019 | $19.76 | 1 | Gilead Sciences, Inc. ($19.76) |
| 2018 | $44.79 | 4 | Gilead Sciences, Inc. ($17.44) |
| 2017 | $123.44 | 8 | Janssen Biotech, Inc. ($54.83) |
All Payment Transactions
29 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/21/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $113.15 | General |
| Category: NEUROSCIENCE | ||||||
| 09/04/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $19.48 | General |
| Category: NEUROSCIENCE | ||||||
| 02/28/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $116.84 | General |
| Category: NEUROSCIENCE | ||||||
| 12/12/2023 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $20.78 | General |
| Category: NEUROSCIENCE | ||||||
| 11/14/2023 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $48.10 | General |
| Category: NEUROSCIENCE | ||||||
| 08/16/2023 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $18.10 | General |
| Category: NEUROSCIENCE | ||||||
| 08/01/2023 | Janssen Pharmaceuticals, Inc | — | Education | In-kind items and services | $28.48 | General |
| 01/31/2023 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $77.92 | General |
| Category: NEUROSCIENCE | ||||||
| 01/18/2023 | Insmed, Inc. | Arikayce (Drug) | Education | In-kind items and services | $16.24 | General |
| Category: Respiratory | ||||||
| 10/04/2022 | Insmed, Inc. | Arikayce (Drug) | Education | In-kind items and services | $16.24 | General |
| Category: Respiratory | ||||||
| 09/12/2022 | Insmed, Inc. | Arikayce (Drug) | Education | In-kind items and services | $16.24 | General |
| Category: Respiratory | ||||||
| 10/05/2021 | BOSTON SCIENTIFIC CORPORATION | VARITHENA (Device) | Food and Beverage | In-kind items and services | $20.63 | General |
| Category: PAIN MANAGEMENT | ||||||
| 12/16/2020 | Insmed, Inc. | — | Education | In-kind items and services | $11.90 | General |
| 08/31/2020 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Education | In-kind items and services | $12.59 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 08/03/2020 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Education | In-kind items and services | $12.59 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 02/10/2020 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Education | In-kind items and services | $12.70 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 02/06/2019 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $19.76 | General |
| 06/13/2018 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $11.36 | General |
| 05/21/2018 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $6.08 | General |
| 05/01/2018 | Allergan Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $13.16 | General |
| Category: ANTI-INFECTIVE | ||||||
| 03/15/2018 | Janssen Biotech, Inc. | PREZCOBIX (Drug) | Food and Beverage | In-kind items and services | $14.19 | General |
| Category: Infectious Diseases & Vaccines | ||||||
| 10/13/2017 | Janssen Biotech, Inc. | PREZCOBIX (Drug) | Food and Beverage | In-kind items and services | $13.97 | General |
| Category: Infectious Diseases & Vaccines | ||||||
| 09/01/2017 | Allergan Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $16.87 | General |
| Category: ANTI-INFECTIVE | ||||||
| 06/17/2017 | Allergan Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $25.63 | General |
| Category: ANTI-INFECTIVE | ||||||
| 06/16/2017 | Janssen Biotech, Inc. | PREZCOBIX (Drug) | Food and Beverage | In-kind items and services | $12.32 | General |
| Category: Infectious Diseases & Vaccines | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 21 | 1,107 | 301,763 | $887,067 | $202,548 |
| 2022 | 20 | 1,265 | 199,775 | $1.1M | $230,298 |
| 2021 | 19 | 1,281 | 337,798 | $1.7M | $275,766 |
| 2020 | 21 | 1,394 | 352,010 | $1.3M | $300,674 |
Total Patients
5,047
Total Services
1,191,346
Medicare Billing
$1.0M
Procedure Codes
81
All Medicare Procedures & Services
81 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 157 | 491 | $73,650 | $46,928 | 63.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 70 | 717 | $161,325 | $35,518 | 22.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 181 | 204 | $81,192 | $27,946 | 34.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 135 | 254 | $34,290 | $17,787 | 51.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 105 | 258 | $28,380 | $16,412 | 57.8% |
| 96521 | Refilling and maintenance of portable pump | Office | 2023 | 28 | 159 | $51,675 | $15,530 | 30.1% |
| J0878 | Injection, daptomycin, 1 mg | Office | 2023 | 38 | 291,439 | $51,578 | $12,709 | 24.6% |
| 96374 | Injection of drug or substance into vein | Office | 2023 | 30 | 250 | $18,750 | $7,238 | 38.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 41 | 41 | $10,455 | $5,238 | 50.1% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 28 | 206 | $41,200 | $4,619 | 11.2% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 17 | 152 | $19,000 | $2,435 | 12.8% |
| J0692 | Injection, cefepime hydrochloride, 500 mg | Office | 2023 | 24 | 1,910 | $85,950 | $1,876 | 2.2% |
| J3370 | Injection, vancomycin hcl, 500 mg | Office | 2023 | 15 | 886 | $42,085 | $1,666 | 4.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 18 | 18 | $3,780 | $1,621 | 42.9% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2023 | 26 | 2,980 | $149,000 | $1,216 | 0.8% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 33 | 56 | $2,240 | $975.78 | 43.6% |
| 36592 | Collection of blood sample from central venous tube | Office | 2023 | 21 | 43 | $2,365 | $961.91 | 40.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 39 | 84 | $840.00 | $697.20 | 83.0% |
| J7050 | Infusion, normal saline solution, 250 cc | Office | 2023 | 70 | 1,344 | $21,504 | $688.98 | 3.2% |
| J7030 | Infusion, normal saline solution , 1000 cc | Office | 2023 | 18 | 217 | $6,944 | $432.44 | 6.2% |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | Office | 2023 | 13 | 54 | $864.00 | $54.06 | 6.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 189 | 694 | $104,100 | $56,072 | 53.9% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 73 | 926 | $208,350 | $47,920 | 23.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 213 | 246 | $97,908 | $38,581 | 39.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 134 | 306 | $33,660 | $17,290 | 51.4% |
About Dr. Marie Kima, M.D
Dr. Marie Kima, M.D is a Infectious Disease healthcare provider based in Gainesville, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/02/2006. The National Provider Identifier (NPI) number assigned to this provider is 1699733402.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Marie Kima, M.D has received a total of $749.97 in payments from pharmaceutical and medical device companies, with $249.47 received in 2024. These payments were reported across 29 transactions from 9 companies. The most common payment nature is "Food and Beverage" ($616.91).
As a Medicare-enrolled provider, Kima has provided services to 5,047 Medicare beneficiaries, totaling 1,191,346 services with total Medicare billing of $1.0M. Data is available for 4 years (2020–2023), covering 81 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Gainesville, FL
- Active Since 05/02/2006
- Last Updated 12/05/2014
- Taxonomy Code 207RI0200X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1699733402
Products in Payments
- QULIPTA (Drug) $374.11
- PREZCOBIX (Drug) $69.02
- Arikayce (Drug) $48.72
- UBRELVY (Drug) $40.26
- ZERBAXA (Drug) $37.88
- AVYCAZ (Drug) $37.74
- DALVANCE (Drug) $30.03
- VARITHENA (Device) $20.63
- SUSTIVA (Drug) $14.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Gainesville
Lennox Archibald, Md, MD
Infectious Disease — Payments: $2.9M
Infectious Disease $2.9M
Dr. Cornelius Clancy, Md, MD
Infectious Disease — Payments: $166,876
Infectious Disease $166,876
Adam Bressler, M.d, M.D
Infectious Disease — Payments: $123,008
Infectious Disease $123,008
Wendy Garlington, Md, MD
Infectious Disease — Payments: $1,427
Infectious Disease $1,427
Gary Wang, Md, Phd, MD, PHD
Infectious Disease — Payments: $850.64
Infectious Disease $850.64
Dr. Guy El Helou, M.d, M.D
Infectious Disease — Payments: $656.94
Infectious Disease $656.94